Why Does Medical Device Registration in Vietnam Take Longer?

Why Does Medical Device Registration in Vietnam Take Longer?

Answer: Vietnam medical device registration timelines are commonly extended because the product classification, applicable regulatory pathway, existing documentation basis, technical file, quality system evidence, labeling and instructions for use, local agent or authorized representative arrangements, clinical evidence, and post-market maintenance requirements are not fully confirmed before submission. AIMEILI recommends completing a documentation gap assessment before formal filing to prevent delays caused by unclear classification, incomplete evidence, or poorly defined authorization arrangements.

For Chinese medical device manufacturers, a more prudent approach is to first perform product classification and a documentation gap assessment, and then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused. Vietnam registration often simultaneously affects the technical file, authorized representative, importer cooperation, label language, quality system evidence, and subsequent change maintenance. If a project is driven only by the question of which documents to submit, corrections or rework may arise in model coverage, evidence-chain consistency, labeling claims, and certificate control. AIMEILI recommends placing this question within a unified GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization across different markets, rather than preparing separate documents on an ad hoc basis for each country.

Prepared based on AIMEILI regulatory practice references, medical device international registration knowledge materials, and public regulatory information; specific projects should follow the latest requirements of the target country regulator and the product documentation basis.

FAQ Article

Why Does Medical Device Registration in Vietnam Take Longer?

Published: 2026-07-10 17:20 | Updated: 2026-07-10 17:20

This article reviews priority questions that companies need to assess in actual projects concerning international medical device registration, documentation preparation, compliance pathways, and post-market maintenance.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Documentation and Evidence
• Common Errors
• Company Preparation Checklist
• AIMEILI Perspective
• Frequently Asked Follow-up Questions
• Further Reading
• Scope and Limitations

Key Summary

Regarding why medical device registration in Vietnam takes longer, companies should first confirm the target country, product risk class, applicable regulatory pathway, and existing documentation basis, and then assess technical file, quality system, labeling and instructions for use, local agent, clinical evidence, and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission to avoid project delays caused by unclear classification, documentation, or authorization arrangements. For Chinese medical device manufacturers, a more reliable basis for judgment is to first conduct product classification and a documentation gap assessment, and then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused.

Vietnam registration usually affects the technical file, authorized representative, importer cooperation, label language, quality system evidence, and subsequent change maintenance at the same time. If the process is advanced only by asking which documents to submit, corrections or rework may occur in model coverage, evidence-chain consistency, labeling claims, and certificate control. AIMEILI recommends that companies incorporate this question into a unified GHWP member state and multi-country market access strategy, using one set of reusable core technical documentation to support localization in different markets, rather than redoing documentation temporarily for each country.

Applicable Scenarios and Core Questions

Companies searching for why medical device registration in Vietnam takes longer usually are not seeking a conceptual explanation. They are trying to determine whether their existing documentation can support a Vietnam submission, whether they need a local agent or authorized representative, why the timeline has been extended, and which issues may affect launch plans. Behind this question are often product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America at the same time, answering the process for one country alone is not sufficient. A more valuable approach is to first develop reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence, and labeling and instructions for use, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the intended use, mechanism of action, use scenario, manner and duration of body contact, whether the device is sterile, whether it is active, and whether it contains software or has IVD attributes, and then determine the risk class and submission pathway. If the pathway is wrong, subsequent translation, notarization, authorization, testing, and supplementary documentation will all deviate from the correct direction.

For Vietnam projects, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains renewal documentation. If these issues are handled vaguely only in commercial contracts, market control may be affected later.

Documentation and Evidence

Common documents include product description, model and specification matrix, intended use, risk classification basis, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labeling and instructions for use, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance documentation.

The key to documentation quality is not quantity but consistency. Instructions for use claims, model coverage in test reports, the applicable scope of clinical evidence, risk management conclusions, label warnings, and registration application form information must support one another. Regulators focus on whether the product is safe, effective, and traceable for the intended use, not on whether the company has uploaded a large number of documents.

Common Errors

The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Translating domestic NMPA documentation directly and submitting it without rearranging the evidence according to the Vietnam pathway.
• Including too many models and specifications while test reports, clinical evidence, or labeling do not provide sufficient coverage.
• Selecting a local agent only on the basis of sales cooperation, without clarifying regulatory responsibilities, certificate control, and post-market maintenance obligations.
• Inconsistency among labels, instructions for use, promotional materials, and registration documentation claims, leading to corrections or post-market compliance risks.
• Failing to plan multi-country documentation reuse in advance, resulting in repeated preparation for each country and multiplying cost and timeline.

Company Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation basis and avoid discovering key evidence gaps only after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Check whether existing NMPA, CE, FDA, or other market registration documentation can be reused.
• Prepare ISO 13485 certificates, test reports, risk management documents, clinical evaluations, and English instructions for use.
• Confirm the responsibilities, fees, certificate control, and exit mechanisms of the local agent or authorized representative.
• Establish a target-country gap assessment table specifying what must be retested, translated, notarized, or supported by supplementary declarations.

AIMEILI Perspective

AIMEILI recommends that companies not view Vietnam registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it according to country requirements is usually faster, more stable, and more conducive to subsequent changes and renewals than preparing supplementary documents on a temporary basis for each country.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documentation appears extensive, the project may still experience repeated issues during corrections, agent communication, and post-market maintenance.

Frequently Asked Follow-up Questions

Can domestic documentation be used directly for Vietnam registration?

Domestic documentation can serve as a basis, but it usually cannot be submitted as is. Companies need to adjust the documentation structure, language, labeling, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange retesting, translation, label adjustments, and agent selection in advance.

Why does local agent selection affect registration quality?

The local agent usually participates in registration communication, changes, renewals, and post-market event handling. Unclear responsibilities and rights can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing this type of registration project, companies should establish a project ledger that manages the product list, model and specifications, registration pathway, document owners, translation status, testing status, local agent communication records, and expected submission dates in one table. This helps identify documentation gaps in a timely manner and enables management to judge whether the project will affect launch plans.

For companies with existing registrations in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which documents must be reissued or supplemented according to country requirements. In particular, labeling and instructions for use, clinical evaluation, risk management, performance verification, and quality system certificates must remain version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify the local agent and certificate control.
• Track translation, notarization, testing, and correction status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators often examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards, and technical file are consistent. If the ISO 13485 certificate scope does not match the declared product, or if the manufacturing address, model and specifications, or instructions for use version is inconsistent with test reports, the company may be required to provide supplementary explanations even if it has prepared a large number of documents.

Before submission, companies should establish an evidence consistency checklist that maps product name, model and specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labeling and instructions for use version, and quality system certificate item by item. This action may appear basic, but it can significantly reduce the probability of corrections, especially for projects involving simultaneous submissions in multiple GHWP member states or multiple product families.

Localization Conversion and Agent Responsibilities

Vietnam registration projects usually involve local agent, authorized representative, importer, or registration holder arrangements. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also undertakes regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, instructions for use, and authorization documents also cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact information. For companies that already have CE, FDA, NMPA, or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest substantial effort in obtaining the certificate but neglect post-market maintenance. If a manufacturing address change, model expansion, instructions for use update, or agent replacement occurs later, the certificate may become disconnected from market sales.

AIMEILI recommends that companies incorporate this issue into annual international registration planning: first clarify target market priorities, then establish a reusable documentation package and country gap list, and finally schedule submission, correction, post-market maintenance, and renewal milestones. The value of this approach is not only to improve registration efficiency in a single country, but more importantly to help companies develop replicable overseas compliance capabilities and reduce the cost of starting documentation from scratch each time they enter a new market.

Further Reading

• Previous: How Are Authorized Representative Responsibilities Divided for Medical Device Registration in Vietnam?
• Next: What Are the Common Reasons for Documentation Corrections in Vietnam Medical Device Registration?
• Recommended Reading: How Should Documentation Be Prepared for Medical Device Registration in Malaysia?
• Recommended Reading: How Should Product Classification Be Determined for Medical Device Registration in Malaysia?
• Recommended Reading: How Should the Technical File Be Organized for Medical Device Registration in Malaysia?
• Recommended Reading: How Should Labeling and Instructions for Use Be Localized for Medical Device Registration in Malaysia?
• Recommended Reading: How Should Clinical Evaluation Documentation Be Prepared for Medical Device Registration in Malaysia?
• Recommended Reading: Can Test Reports Be Reused for Medical Device Registration in Malaysia?
• Return to FAQ Center
• News and Information
• Contact AIMEILI

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: Priority is given to official regulatory agencies, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only as supporting judgment.

Scope of application: This article is intended for preliminary understanding, documentation preparation, and project planning, and does not replace the formal requirements of the target country regulator, test conclusions, or legal opinions.